PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® – GM-CSF Combination to Overcome Tumor Immune Suppression

NEXT STORY
PHASTAR to Present at DIA 2019 Global Annual Meeting
PREV STORY
Immuron to Commence US Non-Deal Institutional Investor Roadshow
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® – GM-CSF Combination to Overcome Tumor Immune Suppression

NEXT STORY
PHASTAR to Present at DIA 2019 Global Annual Meeting
PREV STORY
Immuron to Commence US Non-Deal Institutional Investor Roadshow
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019

author_avatar
NASDAQ Market News

Aspen Valley Hospital and The Steadman Clinic Form Strategic Partnership

author_avatar
NASDAQ Market News

Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

author_avatar
NASDAQ Market News